Publications by authors named "Jessica D Sun"

Claim this Profile
D
Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor Immunosuppression.
Jared T Moore, Hiroyuki Kawai, Brian R Blank, Kejia Wu, Chien-Hung Yeh, Jessica D Sun, Daqing Sun

J Med Chem· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.
Melissa R Junttila, Claire E Repellin, Sumeet Salaniwal, Robert Warne, Younho Lee, Jessica D Sun

Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation.
Gregory B Craven, Hang Chu, Jessica D Sun, Jordan D Carelli, Brittany Coyne

Nature· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.
Christopher T Chen, Vishesh Khanna, Shivaani Kummar, Raghad M Abdul-Karim, David Sommerhalder, Jessica D Sun

Cancer Res Commun· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer.
Jessica D Sun, Qian Liu, Jingli Wang, Dharmendra Ahluwalia, Damien Ferraro

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial ablation of the orexin field induces a sub-narcoleptic phenotype in a conditional mouse model of orexin neurodegeneration.
Sarah Wurts Black, Jessica D Sun, Pamela Santiago, Alex Laihsu, Nikki Kimura

Sleep· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
Andrew Brenner, Richard Zuniga, Jessica D Sun, John Floyd, Charles P Hart

Neuro Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.
Sushil Kumar, Jessica D Sun, Libo Zhang, Reza Bayat Mokhtari, Bing Wu

Transl Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.
Rafael Duran, Sahar Mirpour, Vasily Pekurovsky, Shanmugasundaram Ganapathy-Kanniappan, Cory F Brayton, Jessica D Sun

Clin Cancer Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
Jessica D Sun, Qian Liu, Dharmendra Ahluwalia, Damien J Ferraro, Yan Wang

Cancer Biol Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Jessica D Sun, Qian Liu, Dharmendra Ahluwalia, Wenwu Li, Fanying Meng

Cancer Biol Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
Jessica D Sun, Dharmendra Ahluwalia, Qian Liu, Wenwu Li, Yan Wang

Am J Cancer Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
Sarah G J A Peeters, Catharina M L Zegers, Rianne Biemans, Natasja G Lieuwes, Ruud G P M van Stiphout, Jessica D Sun

Clin Cancer Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Fanying Meng, Deepthi Bhupathi, Jessica D Sun, Qian Liu, Dharmendra Ahluwalia

BMC Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Qian Liu, Jessica D Sun, Jingli Wang, Dharmendra Ahluwalia, Amanda F Baker

Cancer Chemother Pharmacol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.
Abdel Kareem Azab, Jinsong Hu, Phong Quang, Feda Azab, Costas Pitsillides, Jessica D Sun

Blood· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Jessica D Sun, Qian Liu, Jingli Wang, Dharmendra Ahluwalia, Damien Ferraro

Clin Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.
Jian-Xin Duan, Xiaohong Cai, Fanying Meng, Jessica D Sun, Qian Liu

J Med Chem· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Jinsong Hu, Damian R Handisides, Els Van Valckenborgh, Hendrik De Raeve, Eline Menu, Jessica D Sun

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis